Hmdb loader

Showing metabocard for 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole (HMDB0060964)

Jump To Section:
IdentificationTaxonomyOntologyPhysical propertiesSpectraBiological propertiesConcentrationsLinksReferencesXML
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2013-07-09 16:09:50 UTC
Update Date2019-07-23 07:15:29 UTC
HMDB IDHMDB0060964
Secondary Accession Numbers
  • HMDB60964
Metabolite Identification
Common Name5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole
Description5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiadiazole is one of the two major metabolites of tizanidine (PMID: 9929503 , 19961320 ). Tizanidine (trade names Zanaflex, Sirdalud) is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist. It is used to treat the spasms, cramping, and tightness of muscles caused by medical problems such as multiple sclerosis, spastic diplegia, back pain, or certain other injuries to the spine or central nervous system. It is also prescribed off-label for migraine headaches, as a sleep aid, and as an anticonvulsant (Wikipedia).
Structure
Data?1563866128
MOL3D MOLSDF3D SDFPDB3D PDBSMILESInChI

MOL for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)


  Mrv1652305271919272D          

 17 19  0  0  0  0            999 V2000
    2.2413   -0.3751    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    5.6469   -1.2002    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.8695    1.6829    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6703    0.4499    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2020    0.5269    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1654   -0.5363    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1654   -1.8640    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0625    1.8544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6500    1.1399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9558    0.8624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6703   -0.3751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3846   -0.7876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3846   -1.6127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9558   -0.7876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6703   -2.0252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9558   -1.6127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8295    1.0536    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1 14  1  0  0  0  0
  2  6  1  0  0  0  0
  2  7  1  0  0  0  0
  3  8  1  0  0  0  0
  3 10  1  0  0  0  0
  4 10  1  0  0  0  0
  4 11  1  0  0  0  0
  5  9  1  0  0  0  0
  5 10  2  0  0  0  0
  6 12  2  0  0  0  0
  7 13  2  0  0  0  0
  8  9  1  0  0  0  0
 11 12  1  0  0  0  0
 11 14  2  0  0  0  0
 12 13  1  0  0  0  0
 13 15  1  0  0  0  0
 14 16  1  0  0  0  0
 15 16  2  0  0  0  0
  9 17  2  0  0  0  0
M  END
Download

3D MOL for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)

HMDB0060964
     RDKit          3D
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole
 23 25  0  0  0  0  0  0  0  0999 V2000
   -3.6732    2.5241    0.1763 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0554    1.4140    0.0656 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5345    0.2986   -0.7553 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4396   -0.6776   -0.6503 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4888   -0.1601    0.2684 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3182   -0.9156    0.6472 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9678   -0.5910    0.1582 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0301   -1.3652    0.5713 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8225   -2.7161    1.6683 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    3.3092   -1.0795    0.1141 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4590   -0.0223   -0.7421 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3807    0.7807   -1.1750 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4881    1.8172   -2.0071 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9235    2.3862   -2.1679 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.1528    1.2840   -1.1632 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1343    0.4931   -0.7222 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8451    1.0125    0.6624 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4270   -0.2231   -0.3235 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6430    0.5302   -1.8204 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4421   -1.5598   -1.1867 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4161   -1.7221    1.2973 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.1483   -1.6827    0.4339 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.4667    0.1745   -1.0802 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
  5 17  2  0
 17  2  1  0
 16  7  1  0
 16 12  1  0
  3 18  1  0
  3 19  1  0
  4 20  1  0
  6 21  1  0
 10 22  1  0
 11 23  1  0
M  END
Download

3D SDF for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)


  Mrv1652305271919272D          

 17 19  0  0  0  0            999 V2000
    2.2413   -0.3751    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    5.6469   -1.2002    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.8695    1.6829    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6703    0.4499    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2020    0.5269    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1654   -0.5363    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1654   -1.8640    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0625    1.8544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6500    1.1399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9558    0.8624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6703   -0.3751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3846   -0.7876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3846   -1.6127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9558   -0.7876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6703   -2.0252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9558   -1.6127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8295    1.0536    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1 14  1  0  0  0  0
  2  6  1  0  0  0  0
  2  7  1  0  0  0  0
  3  8  1  0  0  0  0
  3 10  1  0  0  0  0
  4 10  1  0  0  0  0
  4 11  1  0  0  0  0
  5  9  1  0  0  0  0
  5 10  2  0  0  0  0
  6 12  2  0  0  0  0
  7 13  2  0  0  0  0
  8  9  1  0  0  0  0
 11 12  1  0  0  0  0
 11 14  2  0  0  0  0
 12 13  1  0  0  0  0
 13 15  1  0  0  0  0
 14 16  1  0  0  0  0
 15 16  2  0  0  0  0
  9 17  2  0  0  0  0
M  END
> <DATABASE_ID>
HMDB0060964

> <DATABASE_NAME>
hmdb

> <SMILES>
ClC1=C(NC2=NC(=O)CN2)C2=NSN=C2C=C1

> <INCHI_IDENTIFIER>
InChI=1S/C9H6ClN5OS/c10-4-1-2-5-8(15-17-14-5)7(4)13-9-11-3-6(16)12-9/h1-2H,3H2,(H2,11,12,13,16)

> <INCHI_KEY>
UAPHNYZODWBPMU-UHFFFAOYSA-N

> <FORMULA>
C9H6ClN5OS

> <MOLECULAR_WEIGHT>
267.69

> <EXACT_MASS>
266.9981587

> <JCHEM_ACCEPTOR_COUNT>
6

> <JCHEM_ATOM_COUNT>
23

> <JCHEM_AVERAGE_POLARIZABILITY>
24.167026618865368

> <JCHEM_BIOAVAILABILITY>
1

> <JCHEM_DONOR_COUNT>
2

> <JCHEM_FORMAL_CHARGE>
0

> <JCHEM_GHOSE_FILTER>
1

> <JCHEM_IUPAC>
2-[(5-chloro-2,1,3-benzothiadiazol-4-yl)amino]-4,5-dihydro-1H-imidazol-4-one

> <ALOGPS_LOGP>
1.58

> <JCHEM_LOGP>
1.2103559563333333

> <ALOGPS_LOGS>
-3.23

> <JCHEM_MDDR_LIKE_RULE>
0

> <JCHEM_NUMBER_OF_RINGS>
3

> <JCHEM_PHYSIOLOGICAL_CHARGE>
0

> <JCHEM_PKA>
19.927437818237532

> <JCHEM_PKA_STRONGEST_ACIDIC>
4.673699267445117

> <JCHEM_PKA_STRONGEST_BASIC>
-0.051372982947768375

> <JCHEM_POLAR_SURFACE_AREA>
79.27000000000001

> <JCHEM_REFRACTIVITY>
64.6455

> <JCHEM_ROTATABLE_BOND_COUNT>
1

> <JCHEM_RULE_OF_FIVE>
1

> <ALOGPS_SOLUBILITY>
1.59e-01 g/l

> <JCHEM_TRADITIONAL_IUPAC>
2-[(5-chloro-2,1,3-benzothiadiazol-4-yl)amino]-1,5-dihydroimidazol-4-one

> <JCHEM_VEBER_RULE>
0

$$$$
Download

3D-SDF for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)

HMDB0060964
     RDKit          3D
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole
 23 25  0  0  0  0  0  0  0  0999 V2000
   -3.6732    2.5241    0.1763 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0554    1.4140    0.0656 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5345    0.2986   -0.7553 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4396   -0.6776   -0.6503 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4888   -0.1601    0.2684 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3182   -0.9156    0.6472 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9678   -0.5910    0.1582 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0301   -1.3652    0.5713 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8225   -2.7161    1.6683 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    3.3092   -1.0795    0.1141 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4590   -0.0223   -0.7421 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3807    0.7807   -1.1750 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4881    1.8172   -2.0071 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9235    2.3862   -2.1679 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.1528    1.2840   -1.1632 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1343    0.4931   -0.7222 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8451    1.0125    0.6624 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4270   -0.2231   -0.3235 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6430    0.5302   -1.8204 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4421   -1.5598   -1.1867 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4161   -1.7221    1.2973 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.1483   -1.6827    0.4339 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.4667    0.1745   -1.0802 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
  5 17  2  0
 17  2  1  0
 16  7  1  0
 16 12  1  0
  3 18  1  0
  3 19  1  0
  4 20  1  0
  6 21  1  0
 10 22  1  0
 11 23  1  0
M  END
Download

PDB for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)

HEADER    PROTEIN                                 27-MAY-19   NONE
TITLE     NULL                                                        
COMPND    NULL                                                        
SOURCE    NULL                                                        
KEYWDS    NULL                                                        
EXPDTA    NULL                                                        
AUTHOR    Marvin                                                      
REVDAT   1   27-MAY-19         0                                  
HETATM    1 Cl   UNK     0       4.184  -0.700   0.000  0.00  0.00          Cl+0
HETATM    2  S   UNK     0      10.541  -2.240   0.000  0.00  0.00           S+0
HETATM    3  N   UNK     0       5.356   3.141   0.000  0.00  0.00           N+0
HETATM    4  N   UNK     0       6.851   0.840   0.000  0.00  0.00           N+0
HETATM    5  N   UNK     0       4.110   0.984   0.000  0.00  0.00           N+0
HETATM    6  N   UNK     0       9.642  -1.001   0.000  0.00  0.00           N+0
HETATM    7  N   UNK     0       9.642  -3.479   0.000  0.00  0.00           N+0
HETATM    8  C   UNK     0       3.850   3.462   0.000  0.00  0.00           C+0
HETATM    9  C   UNK     0       3.080   2.128   0.000  0.00  0.00           C+0
HETATM   10  C   UNK     0       5.517   1.610   0.000  0.00  0.00           C+0
HETATM   11  C   UNK     0       6.851  -0.700   0.000  0.00  0.00           C+0
HETATM   12  C   UNK     0       8.185  -1.470   0.000  0.00  0.00           C+0
HETATM   13  C   UNK     0       8.185  -3.010   0.000  0.00  0.00           C+0
HETATM   14  C   UNK     0       5.517  -1.470   0.000  0.00  0.00           C+0
HETATM   15  C   UNK     0       6.851  -3.780   0.000  0.00  0.00           C+0
HETATM   16  C   UNK     0       5.517  -3.010   0.000  0.00  0.00           C+0
HETATM   17  O   UNK     0       1.548   1.967   0.000  0.00  0.00           O+0
CONECT    1   14                                                            
CONECT    2    6    7                                                       
CONECT    3    8   10                                                       
CONECT    4   10   11                                                       
CONECT    5    9   10                                                       
CONECT    6    2   12                                                       
CONECT    7    2   13                                                       
CONECT    8    3    9                                                       
CONECT    9    5    8   17                                                  
CONECT   10    3    4    5                                                  
CONECT   11    4   12   14                                                  
CONECT   12    6   11   13                                                  
CONECT   13    7   12   15                                                  
CONECT   14    1   11   16                                                  
CONECT   15   13   16                                                       
CONECT   16   14   15                                                       
CONECT   17    9                                                            
MASTER        0    0    0    0    0    0    0    0   17    0   38    0
END
Download

3D PDB for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)

COMPND    HMDB0060964
HETATM    1  O1  UNL     1      -3.673   2.524   0.176  1.00  0.00           O  
HETATM    2  C1  UNL     1      -3.055   1.414   0.066  1.00  0.00           C  
HETATM    3  C2  UNL     1      -3.535   0.299  -0.755  1.00  0.00           C  
HETATM    4  N1  UNL     1      -2.440  -0.678  -0.650  1.00  0.00           N  
HETATM    5  C3  UNL     1      -1.489  -0.160   0.268  1.00  0.00           C  
HETATM    6  N2  UNL     1      -0.318  -0.916   0.647  1.00  0.00           N  
HETATM    7  C4  UNL     1       0.968  -0.591   0.158  1.00  0.00           C  
HETATM    8  C5  UNL     1       2.030  -1.365   0.571  1.00  0.00           C  
HETATM    9 CL1  UNL     1       1.822  -2.716   1.668  1.00  0.00          CL  
HETATM   10  C6  UNL     1       3.309  -1.080   0.114  1.00  0.00           C  
HETATM   11  C7  UNL     1       3.459  -0.022  -0.742  1.00  0.00           C  
HETATM   12  C8  UNL     1       2.381   0.781  -1.175  1.00  0.00           C  
HETATM   13  N3  UNL     1       2.488   1.817  -2.007  1.00  0.00           N  
HETATM   14  S1  UNL     1       0.923   2.386  -2.168  1.00  0.00           S  
HETATM   15  N4  UNL     1       0.153   1.284  -1.163  1.00  0.00           N  
HETATM   16  C9  UNL     1       1.134   0.493  -0.722  1.00  0.00           C  
HETATM   17  N5  UNL     1      -1.845   1.013   0.662  1.00  0.00           N  
HETATM   18  H1  UNL     1      -4.427  -0.223  -0.323  1.00  0.00           H  
HETATM   19  H2  UNL     1      -3.643   0.530  -1.820  1.00  0.00           H  
HETATM   20  H3  UNL     1      -2.442  -1.560  -1.187  1.00  0.00           H  
HETATM   21  H4  UNL     1      -0.416  -1.722   1.297  1.00  0.00           H  
HETATM   22  H5  UNL     1       4.148  -1.683   0.434  1.00  0.00           H  
HETATM   23  H6  UNL     1       4.467   0.175  -1.080  1.00  0.00           H  
CONECT    1    2    2
CONECT    2    3   17
CONECT    3    4   18   19
CONECT    4    5   20
CONECT    5    6   17   17
CONECT    6    7   21
CONECT    7    8    8   16
CONECT    8    9   10
CONECT   10   11   11   22
CONECT   11   12   23
CONECT   12   13   13   16
CONECT   13   14
CONECT   14   15
CONECT   15   16   16
END
Download

SMILES for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)

ClC1=C(NC2=NC(=O)CN2)C2=NSN=C2C=C1
Download

INCHI for HMDB0060964 (5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole)

InChI=1S/C9H6ClN5OS/c10-4-1-2-5-8(15-17-14-5)7(4)13-9-11-3-6(16)12-9/h1-2H,3H2,(H2,11,12,13,16)
Download
View in JSmolView Stereo Labels
Synonyms
ValueSource
2-[(5-Chloro-2,1,3-benzothiadiazol-4-yl)amino]-3,5-dihydro-4H-imidazol-4-oneHMDB
DS 200-717HMDB
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazoleHMDB
Chemical FormulaC9H6ClN5OS
Average Molecular Weight267.69
Monoisotopic Molecular Weight266.9981587
IUPAC Name2-[(5-chloro-2,1,3-benzothiadiazol-4-yl)amino]-4,5-dihydro-1H-imidazol-4-one
Traditional Name2-[(5-chloro-2,1,3-benzothiadiazol-4-yl)amino]-1,5-dihydroimidazol-4-one
CAS Registry Number125292-32-2
SMILES
ClC1=C(NC2=NC(=O)CN2)C2=NSN=C2C=C1
InChI Identifier
InChI=1S/C9H6ClN5OS/c10-4-1-2-5-8(15-17-14-5)7(4)13-9-11-3-6(16)12-9/h1-2H,3H2,(H2,11,12,13,16)
InChI KeyUAPHNYZODWBPMU-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as benzothiadiazoles. These are heterocyclic aromatic compounds containing a benzene ring fused to a thiadiazole ring. Thiadiazole is a five-membered aromatic heterocycle made up of one sulfur atom and two nitrogen atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiadiazoles
Sub ClassNot Available
Direct ParentBenzothiadiazoles
Alternative Parents
Substituents
  • 2,1,3-benzothiadiazole
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiadiazole
  • Imidazole
  • Azole
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
Biological locationSource
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.13 g/LALOGPS
logP1.58ALOGPS
logP1.21ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.67ChemAxon
pKa (Strongest Basic)-0.051ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area79.27 ŲChemAxon
Rotatable Bond Count1ChemAxon
Refractivity64.65 m³·mol⁻¹ChemAxon
Polarizability24.17 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+153.50530932474
DeepCCS[M-H]-151.14730932474
DeepCCS[M-2H]-184.17230932474
DeepCCS[M+Na]+159.59830932474

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022.2.04 minutes32390414
Predicted by Siyang on May 30, 202211.1457 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20222.43 minutes32390414
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid1485.3 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid334.9 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid104.9 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid207.0 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid92.5 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid331.8 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid508.4 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)169.9 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid827.5 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid333.5 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid1135.4 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid277.9 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid268.2 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate518.6 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA251.5 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water155.4 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazoleClC1=C(NC2=NC(=O)CN2)C2=NSN=C2C=C13823.9Standard polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazoleClC1=C(NC2=NC(=O)CN2)C2=NSN=C2C=C12587.3Standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazoleClC1=C(NC2=NC(=O)CN2)C2=NSN=C2C=C12726.5Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TMS,isomer #1C[Si](C)(C)N(C1=NC(=O)CN1)C1=C(Cl)C=CC2=NSN=C122790.8Semi standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TMS,isomer #1C[Si](C)(C)N(C1=NC(=O)CN1)C1=C(Cl)C=CC2=NSN=C122544.7Standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TMS,isomer #1C[Si](C)(C)N(C1=NC(=O)CN1)C1=C(Cl)C=CC2=NSN=C125264.8Standard polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TMS,isomer #2C[Si](C)(C)N1CC(=O)N=C1NC1=C(Cl)C=CC2=NSN=C122809.7Semi standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TMS,isomer #2C[Si](C)(C)N1CC(=O)N=C1NC1=C(Cl)C=CC2=NSN=C122593.7Standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TMS,isomer #2C[Si](C)(C)N1CC(=O)N=C1NC1=C(Cl)C=CC2=NSN=C124709.6Standard polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,2TMS,isomer #1C[Si](C)(C)N1CC(=O)N=C1N(C1=C(Cl)C=CC2=NSN=C12)[Si](C)(C)C2708.0Semi standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,2TMS,isomer #1C[Si](C)(C)N1CC(=O)N=C1N(C1=C(Cl)C=CC2=NSN=C12)[Si](C)(C)C2601.5Standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,2TMS,isomer #1C[Si](C)(C)N1CC(=O)N=C1N(C1=C(Cl)C=CC2=NSN=C12)[Si](C)(C)C4185.1Standard polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C1=NC(=O)CN1)C1=C(Cl)C=CC2=NSN=C122991.4Semi standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C1=NC(=O)CN1)C1=C(Cl)C=CC2=NSN=C122774.9Standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C1=NC(=O)CN1)C1=C(Cl)C=CC2=NSN=C125205.0Standard polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N1CC(=O)N=C1NC1=C(Cl)C=CC2=NSN=C123030.5Semi standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N1CC(=O)N=C1NC1=C(Cl)C=CC2=NSN=C122796.0Standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N1CC(=O)N=C1NC1=C(Cl)C=CC2=NSN=C124775.9Standard polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1CC(=O)N=C1N(C1=C(Cl)C=CC2=NSN=C12)[Si](C)(C)C(C)(C)C3062.4Semi standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1CC(=O)N=C1N(C1=C(Cl)C=CC2=NSN=C12)[Si](C)(C)C(C)(C)C3027.9Standard non polar33892256
5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1CC(=O)N=C1N(C1=C(Cl)C=CC2=NSN=C12)[Si](C)(C)C(C)(C)C4117.8Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole 10V, Positive-QTOFsplash10-014i-0090000000-27032beb0b81065105ea2021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole 20V, Positive-QTOFsplash10-014i-0090000000-27032beb0b81065105ea2021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole 40V, Positive-QTOFsplash10-0079-0970000000-b9ec5a2533b85790aab52021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole 10V, Negative-QTOFsplash10-014i-0090000000-e897dbb6148f6b35d28d2021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole 20V, Negative-QTOFsplash10-001i-9010000000-0ba14923ebc3e508ecdf2021-09-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 5-Chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiazdiazole 40V, Negative-QTOFsplash10-001i-9000000000-3521c8aa3ac28eddc62b2021-09-25Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Membrane (predicted from logP)
Biospecimen Locations
  • Blood
  • Urine
Tissue Locations
  • Kidney
  • Liver
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableNormal
      Not Available
 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableNormal
      Not Available
 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID48059170
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound125355057
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Shellenberger MK, Groves L, Shah J, Novack GD: A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos. 1999 Feb;27(2):201-4. [PubMed:9929503 ]
  2. Kaddar N, Vigneault P, Pilote S, Patoine D, Simard C, Drolet B: Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):102-9. doi: 10.1177/1074248410395020. Epub 2011 Feb 11. [PubMed:21317414 ]
  3. El-Hefnawy AS, Helmy T, El-Assmy MM, Sarhan O, Hafez AT, Dawaba M: Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial. Urology. 2012 Feb;79(2):428-33. doi: 10.1016/j.urology.2011.10.043. Epub 2011 Dec 22. [PubMed:22196407 ]
  4. Zhou SF, Wang B, Yang LP, Liu JP: Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010 May;42(2):268-354. doi: 10.3109/03602530903286476. [PubMed:19961320 ]